Gateley advises on AIM admission of German biopharmaceuticals company

Gateley has advised on the admission to trading of German biopharmaceuticals company Biofrontera on AIM, the London Stock Exchange’s international market for smaller-growing companies.

Biofrontera is also listed in Frankfurt and Düsseldorf and specialises in the development of medical cosmetics and dermatological drugs for the care and treatment of skin diseases.

Nick Emmerson, a corporate partner at Gateley, acted for the nominated adviser and broker.